Fractyl Health, Inc. (NASDAQ:GUTS) Short Interest Up 16.3% in December

Fractyl Health, Inc. (NASDAQ:GUTS) was the target of a large increase in short interest in December. As of December 31st, there was short interest totalling 2,570,000 shares, an increase of 16.3% from the December 15th total of 2,210,000 shares. Currently, 12.5% of the company’s stock are short sold. Based on an average trading volume of 330,200 shares, the days-to-cover ratio is presently 7.8 days.

Fractyl Health Stock Performance

Shares of Fractyl Health stock traded down $0.01 on Friday, hitting $1.80. The stock had a trading volume of 236,286 shares, compared to its average volume of 265,966. Fractyl Health has a 52-week low of $1.74 and a 52-week high of $14.50. The company has a current ratio of 5.58, a quick ratio of 5.57 and a debt-to-equity ratio of 0.60. The stock has a market cap of $86.58 million and a price-to-earnings ratio of -0.15. The company’s 50 day moving average price is $2.11 and its 200 day moving average price is $2.69.

Fractyl Health (NASDAQ:GUTS) last posted its earnings results on Tuesday, November 12th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.02. The firm had revenue of $0.01 million during the quarter. On average, research analysts anticipate that Fractyl Health will post -1.66 EPS for the current year.

Insider Transactions at Fractyl Health

In other news, CEO Harith Rajagopalan sold 96,517 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $2.47, for a total value of $238,396.99. Following the completion of the transaction, the chief executive officer now owns 491,329 shares in the company, valued at approximately $1,213,582.63. This represents a 16.42 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Jay David Caplan sold 64,197 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $2.47, for a total transaction of $158,566.59. Following the completion of the transaction, the insider now owns 153,544 shares of the company’s stock, valued at approximately $379,253.68. The trade was a 29.48 % decrease in their position. The disclosure for this sale can be found here.

Hedge Funds Weigh In On Fractyl Health

Institutional investors have recently modified their holdings of the business. Rhumbline Advisers purchased a new position in shares of Fractyl Health during the second quarter worth about $32,000. Massachusetts Financial Services Co. MA lifted its holdings in Fractyl Health by 2.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 996,383 shares of the company’s stock valued at $4,255,000 after acquiring an additional 25,829 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Fractyl Health during the 2nd quarter worth $61,000. SG Americas Securities LLC acquired a new position in shares of Fractyl Health during the 3rd quarter worth $33,000. Finally, Beta Wealth Group Inc. purchased a new position in shares of Fractyl Health in the 3rd quarter valued at about $44,000.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.